---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-101289"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T16:35:11.043723+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma raises $40M in oversubscribed PIPE financing at $4.80/share

## Summary
- Gross proceeds of $40M from sale of 5,749,152 shares at $4.80 and pre-funded warrants for 2,584,239 shares at $4.7999.
- Led by Suvretta Capital, with Adage Capital, Nantahala Capital, and other healthcare-focused funds participating.
- Proceeds to fund BB-301 clinical development (natural history lead-in and Phase 1b/2a treatment study) and general corporate purposes.
- Kishen Mehta, portfolio manager at Suvretta, to be considered for board appointment.
- Closing expected by April 22, 2024; Leerink Partners and Citizens JMP acting as placement agents.

## SEC filing metadata
- accession: 0001193125-24-101289
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/0001193125-24-101289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/d826712d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-101289
- JSON: https://secwatch.observer/filing/0001193125-24-101289.json
- Plain text: https://secwatch.observer/filing/0001193125-24-101289.txt

## Key facts
- Material Agreements
  Benitec Biopharma Inc. entered into Securities Purchase Agreement with institutional accredited investors valued at aggregate gross proceeds of approximately $40.0 million for 5,749,152 shares at $4.80 per share and (effective 2024-04-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: institutional accredited investors
  - Value: aggregate gross proceeds of approximately $40.0 million for 5,749,152 shares at $4.80 per share and
  - Effective: 2024-04-17
  source text: On April 17, 2024, Benitec Biopharma Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”), (i) an aggregate of 5,749,152 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.80 per share and (ii) in lieu of shares of Common Stock to certain Purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,584,239 shares of Common Stock (the “Warrant Shares”) at a purchase price of $4.7999 per Pre-Funded Warrant (representing the $4.80 per Share purchase price less the exercise price of $0.0001 per Pre-Funded Warrant Share).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/0001193125-24-101289-index.htm
- Material Agreements
  Benitec Biopharma Inc. entered into Registration Rights Agreement with the Purchasers valued at Company agrees to file a registration statement covering resale of Registrable Securities by 30th ca (effective 2024-04-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Value: Company agrees to file a registration statement covering resale of Registrable Securities by 30th ca
  - Effective: 2024-04-22
  source text: In connection with the closing of the Private Placement, on the Closing Date, the Company will enter into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company will agree to register for resale the Shares and the Warrant Shares held by the Purchasers (the “Registrable Securities”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/0001193125-24-101289-index.htm
- Material Agreements
  Benitec Biopharma Inc. entered into Voting Commitment Agreement with the Purchasers valued at Company obligated to use reasonable best efforts to obtain stockholder approval for exercise of Pre- (effective 2024-04-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Value: Company obligated to use reasonable best efforts to obtain stockholder approval for exercise of Pre-
  - Effective: 2024-04-22
  source text: In connection with the Private Placement, the Company intends to enter into a Voting Commitment Agreement with the Purchasers on the Closing Date (the “Voting Commitment Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/0001193125-24-101289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.